Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
Immunic (Nasdaq: IMUX) said it will present additional Phase 2 CALLIPER trial data on vidofludimus calcium (IMU-838) for progressive multiple sclerosis at the 2026 CMSC Annual Meeting. The late-breaking poster reports unified “confirmed disability change” analyses favoring vidofludimus vs placebo. Other posters cite similar safety vs placebo (TEAEs 69.4% vs 68.5%, discontinuations 2.6% each) and no worsening in PHQ-9 depressive thoughts through 120 weeks.
How this was made
The 30-second read
Why it matters
The company is using CMSC to reinforce efficacy interpretation (a unified disability endpoint capturing worsening and improvement), while also addressing investor concerns around mood/PHQ-9 and overall tolerability through up to 120 weeks.
Market read
For IMUX, the incremental catalyst is improved framing of disability outcomes plus reassurance on mood-related PROs and comparable adverse-event rates versus placebo.
What to watch
The release stresses favorable safety and PROs, but does not provide efficacy magnitude/clinical significance details beyond “numerically favored” and model-based analyses; investors may wait for next trial milestones.
Background
Immunic is running the Phase 2 CALLIPER trial in progressive multiple sclerosis with vidofludimus calcium (IMU-838), a direct Nurr1 activator and selective DHODH inhibitor.
Ticker impact
Immunic (IMUX) announced new late-breaking and additional Phase 2 CALLIPER posters for vidofludimus calcium (IMU-838) in progressive MS, emphasizing favorable disability analyses, PROs, and safety.
Near-term sentiment support possible, but magnitude likely limited because this is conference poster data rather than a new primary endpoint readout.
The release adds specific post-hoc statistical framing (Confirmed Disability Change) plus PRO and safety/tolerability details through 120 weeks, which can improve perceived efficacy and tolerability, though it does not state a new regulatory-grade primary endpoint result.
Market effects
Supports the broader progressive MS small-molecule/immune-modulation narrative by highlighting disability trajectory endpoints and tolerability consistency.
Limited; primarily US-listed biotech sentiment tied to conference catalysts.
Moderate for MS investors globally, but the data are conference/poster-level rather than definitive trial readouts.
Counterpoint
Because the key disability framework is post-hoc and conference-poster based, the market may discount it versus a pre-specified primary endpoint or statistically powered confirmatory result.
Key entities
- companyImmunic, Inc.
Late-stage biotech developing oral therapies for neurologic diseases; presenting new Phase 2 CALLIPER posters for IMU-838 at CMSC 2026.
- drugVidofludimus calcium (IMU-838)
Investigational oral small molecule for progressive multiple sclerosis; assessed in Phase 2 CALLIPER.
- clinical_trialCALLIPER trial
Phase 2 study in progressive MS providing the data for the three CMSC posters.
- conferenceCMSC Annual Meeting 2026
Consortium of Multiple Sclerosis Centers meeting where the posters are presented May 27-29, 2026.
